Published in the New England Journal of Medicine (2008), the CAMMS223 trial provides critical insights into the efficacy of Alemtuzumab compared to Interferon Beta-1a in patients with early, relapsing-remitting multiple sclerosis (RRMS). This phase 2, randomized, blinded study highlights the … Read More
